Biopsy Devices Market Report

Global Biopsy Devices Market Size

The global biopsy devices market was valued at USD 2382.61 million in 2024. The global biopsy devices market is expected to have a 7.47% CAGR from 2025 to 2033 and be worth USD 4556.57 million by 2033 from USD 2560.69 million in 2025.

The biopsy device is designed to extract tissue specimens for histopathological, molecular, and cytological analysis, forming the cornerstone of diagnostic oncology, infectious disease detection, and autoimmune disorder evaluation. As per the World Health Organization, over 19.3 million new cancer cases were diagnosed globally in 2020, with nearly 10 million deaths attributable to malignancies, emphasizing the irreplaceable role of accurate tissue acquisition. In the United States alone, millions of tissue biopsies are performed annually, according to a study, with core needle and vacuum-assisted systems accounting for a portion of procedures in breast and prostate diagnostics. The increasing reliance on minimally invasive techniques has redefined clinical workflows by shifting from open surgical excisions to image-guided interventions that reduce hospital stays and complications.

MARKET DRIVERS

Rising Cancer Incidence in Aging Populations Driving Demand

The escalating global burden of cancer in aging populations is fuelling the expansion of the biopsy device market. According to the research, the number of individuals aged 65 and older is projected to surge by 2050, a demographic cohort with significantly elevated cancer incidence rates. The shift toward population-wide screening programs, such as mammography-guided core needle biopsies in the U.S., where millions of breast biopsies are conducted yearly, according to the study, has institutionalized biopsy procedures as standard care. This isn’t merely reactive medicine; it’s preventive infrastructure. The exponential growth in required tissue samples, fueled by rising life expectancy and expanding screening protocols, drives the innovation and adoption of high-accuracy automated biopsy platforms.

Integration of Real-Time Imagining Enhances Accuracy

The integration of real-time imaging technologies with biopsy systems, transforming procedural accuracy and clinical outcomes, is accelerating the growth of the biopsy device market. According to the research, ultrasound-guided, MRI-guided, and CT-guided biopsies account for a share of all interventional procedures in developed healthcare systems, up from a decade ago. The convergence of high-resolution imaging with robotic-assisted needle guidance, such as in the Percepta Genomic Sequencing Classifier system used in lung nodule diagnostics, has reduced inconclusive results. This synergy between diagnostics and intervention has created a feedback loop.

MARKET RESTRAINTS

High Costs and Infrastructure Gaps Hindering Adoption

The prohibitive cost of advanced systems and associated infrastructure in low- and middle-income countries is a key factor that impacts the expansion of the biopsy device market. In sub-Saharan Africa, a smaller share of hospitals possess functional imaging equipment compatible with modern biopsy guidance, forcing reliance on blind palpation techniques with failure rates exceeding. Even within high-income nations, reimbursement constraints persist. This mismatch between technological capability and economic viability creates a diagnostic divide, where patients in resource-constrained settings face delayed or inaccurate diagnoses.

Regulatory Fragmentation and Lengthy Approval Cycles

Regulatory fragmentation and prolonged approval cycles across key jurisdictions hinder the growth of the biopsy device market. The median time for clearance of novel biopsy devices has extended to several days, up from that in 2018, primarily due to heightened scrutiny over software-integrated components and AI-assisted targeting algorithms. Similarly, the European Medicines Agency’s notified bodies now require additional clinical validation for devices incorporating machine learning, adding months to market entry timelines, according to a study. These bureaucratic delays disproportionately affect small innovators lacking capital to sustain multi-jurisdictional submissions, which results in market stagnation and reduced competition.

MARKET OPPORTUNITIES

Emergence of Point-of-Care Biopsy Systems in Decentralized Settings

The expansion of point-of-care biopsy systems into decentralized clinical environments such as rural clinics and mobile diagnostic units creates new opportunities to expand the biopsy device market. These compact, battery-powered systems, such as the BD Onclarity platform, are designed for minimal maintenance, which requires no dedicated radiology suite. When integrated with AI-driven triage algorithms that prioritize high-risk lesions for immediate sampling, they reduce diagnostic latency from weeks to hours. Telepathology networks are expanding. This involves fusing portable biopsy hardware with cloud-based pathology analytics. The result is a scalable model for early detection beyond urban centers.

Hybrid Workflows Combining Tissue and Liquid Biopsies

The integration of biopsy technology with liquid biopsy companion diagnostics is enabling sequential tissue confirmation and genomic profiling, providing potential opportunities for the biopsy device market. According to the study, a portion of newly diagnosed non-small cell lung cancer patients now undergo concurrent tissue biopsy and plasma-based ctDNA testing, with tissue samples serving as the gold standard to validate liquid biopsy findings. Companies have developed hybrid workflows where a single needle insertion yields both histological material and molecular analytes through dual-channel devices, which reduces procedural burden.

MARKET CHALLENGES

Shortage of Skilled Specialists as a Market Constraint

The persistent shortage of trained interventional radiologists and pathologists capable of operating and interpreting advanced biopsy systems is another obstacle in the biopsy device market. According to the study, there are fewer interventional radiologists per million people in low-income countries, compared to those in high-income nations. In the U.S., the demand for biopsy-trained specialists is projected to outstrip supply, even as procedural volumes rise. This human capital gap forces clinicians to rely on suboptimal techniques or delay procedures, increasing diagnostic uncertainty and patient anxiety.

Complications and Variability in Biopsy Procedures

The risk of procedural complications stemming from operator variability and inconsistent device handling protocols limits the growth of the biopsy device market. In community hospitals without dedicated interventional suites, the rate of repeat biopsies due to inadequate sampling surged, versus that in academic centers. Furthermore, the absence of universally adopted safety standards for needle retraction mechanisms and contamination control increases cross-infection risks, particularly in settings with limited sterilization capacity. Despite advancements in automation, manual handling remains prevalent in a portion of procedures globally. This inconsistency weakens diagnostic reliability and erodes trust in biopsy-derived molecular data, which creates a hidden burden on healthcare systems through redundant testing, litigation, and prolonged patient management cycles.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Insights

The consumables segment led the biopsy device market by accounting for a substantial share in 2024. The growth of the consumables segment is primarily driven by the fundamental biological reality that each biopsy procedure consumes disposable components, needles, cartridges, suction modules, preservation vials, and tissue transport media. The rise of minimally invasive techniques like core needle and vacuum-assisted biopsies has amplified this dependency. Moreover, regulatory mandates for single-use items to mitigate cross-contamination, such as those enforced by the CDC’s infection control guidelines, have institutionalized disposability. Instruments are durable capital assets. Consumables are recurring revenue engines tied directly to procedural volume, which makes them the most predictable and scalable segment in the value chain.

The instruments segment is projected to expand at a CAGR of 9.4% from 2025 to 2033. The rapid expansion is fueled by the integration of AI-enabled navigation systems and robotic precision platforms into biopsy workflows. Apart from these, demand for smart instruments with real-time tissue characterization, like the BioIntelliSense Biosticker integrated with biopsy needles to monitor tissue elasticity during sampling, is gaining traction in European academic hospitals. These instruments are no longer passive tools; they are data-generating nodes in digital pathology ecosystems by justifying premium pricing and replacement cycles tied to software updates rather than mechanical wear.

By Application Insights

The medical diagnosis segment dominated the biopsy device market by capturing a substantial share in 2024. The dominance of the medical diagnosis segment is mainly due to the centrality of tissue acquisition in oncology, autoimmune disorders, and infectious disease confirmation. In Europe, a portion of all cancer diagnoses relies on histopathological validation via biopsy, with lung, breast, and prostate cancers accounting for millions of these cases annually. Even in low-resource settings, biopsy remains the gold standard for tuberculosis granuloma detection and lymphoma subtyping. The expansion of screening programs has embedded biopsy into the preventive medicine infrastructure.

The genetic fingerprinting segment is anticipated to witness the fastest CAGR of 15.8% over the forecast period due to the convergence of biopsy-derived DNA extraction with high-throughput genomic profiling in clinical forensics and personalized medicine. In Australia, there has been an increase in biopsy-based forensic DNA profiling for unidentified remains, driven by cold case re-investigations using advanced SNP arrays. The technique is also being deployed in mass disaster victim identification.

By End User Insights

The pharmaceutical and biology segment was the largest and held a 56.8% share of the global biopsy device market in 2024. The growth of the pharmaceutical and biology segment is attributed to the industry’s reliance on human tissue samples for preclinical drug efficacy testing, biomarker discovery, and tumor microenvironment modeling. Companies like Novartis and Roche maintain proprietary tissue biobanks containing a large number of anonymized samples, sourced exclusively through partnered hospital biopsy networks in the U.S., Germany, and South Korea. The shift toward organoid and 3D tumor model development further intensifies demand. Regulatory agencies mandate patient-derived tissue validation for accelerated approvals by making pharmaceutical entities the most consistent and highest-volume purchasers of biopsy infrastructure.

The contract research organizations (CROs) segment is likely to experience the fastest CAGR of 14.2% from 2025 to 2033. The swift expansion of the contract research organizations (CROs) segment is propelled by the decentralization of clinical trial logistics and the rising cost of in-house tissue handling. A percentage of global Phase III oncology trials outsource biopsy processing to specialized CROs like LabCorp and Syneos Health, which operate centralized pathology hubs equipped with automated staining, cryo-preservation, and digital slide scanning systems.

REGIONAL ANALYSIS

North America Biopsy Devices Market Analysis

North America outperformed other regions in the biopsy devices market by capturing 41.8% of the share in 2024, with the United States, where the density of diagnostic imaging centers and cancer screening protocols creates unmatched procedural volume. According to the study, a large number of new cancer diagnoses occur annually in the U.S., driving the highest per capita biopsy rate globally. The region leads in the adoption of image-guided robotic systems, with a portion of academic hospitals utilizing MRI-compatible biopsy platforms, as per research. Medicare reimbursement policies support complex interventions, and private insurers cover next-generation sequencing-linked biopsies under expanded diagnostic coding. The presence of a percentage of global biopsy device manufacturers, including Boston Scientific, BD, and Philips, further consolidates North America’s position as both innovator and primary consumer. Its regulatory maturity enables rapid commercialization, while its healthcare infrastructure ensures near-universal access to tissue-based diagnostics, which makes it the undisputed epicenter of biopsy-driven precision medicine.

Europe Biopsy Devices Market Analysis

Europe was the next prominent region in the biopsy device market by capturing 29.9% of share in 2024, which is led by Germany, France, and the UK, where universal healthcare systems ensure equitable access to diagnostic technologies. EU citizens receive biopsy-based cancer diagnosis within days of suspicion, the fastest turnaround among major economies. Germany performs millions of tissue biopsies annually, guided by ultrasound or CT, according to the study. The region’s strength lies in its standardized pathology networks and public-private partnerships like the European Molecular Biology Laboratory’s biobanking initiative, which curates 1.2 million annotated tissue samples for translational research. Reimbursement frameworks in Scandinavia incentivize minimally invasive techniques, reducing hospital stays.

Asia Pacific Biopsy Devices Market Analysis

Asia Pacific is expected to be the most lucrative region in the biopsy devices market and is the fastest-expanding region. China dominates this segment, performing millions of biopsies annually, the highest absolute volume worldwide, as per a study, driven by aggressive lung and gastric cancer screening campaigns following the 2021 national early detection initiative. According to the study, India’s biopsy volume has grown year-over-year since 2020, with private hospitals adopting automated core needle systems to meet rising urban demand. Japan leads in technological sophistication, with a portion of prostate biopsies now robotically assisted. Yet, disparities persist. Rural areas in Indonesia and the Philippines still rely on fine-needle aspiration due to a lack of imaging infrastructure.

Latin America Biopsy Devices Market Analysis

Latin America market growth is likely to grow with Brazil and Mexico as primary drivers, though access remains highly uneven. Cancer patients in the region receive histopathological confirmation before treatment due to limited laboratory capacity. Brazil accounts for a percentage of regional biopsy activity, performing a large number of procedures annually, as per the study, with public hospitals increasingly adopting ultrasound-guided core biopsy systems under SUS funding. Chile and Argentina have pioneered telepathology networks that transmit biopsy slides from remote clinics to central labs, which is reducing diagnostic delays from weeks to hours.

Middle East and Africa Biopsy Devices Market Analysis

Middle East and Africa are likely to grow steadily in the biopsy devices market. In some regions, oncology and pathology infrastructure matches advanced global standards, with widespread access to imaging-guided systems and large, AI-integrated labs handling high volumes of biopsies. Other areas face severe shortages, with only a small fraction of suspected cases receiving diagnostic testing due to limited personnel, equipment, and transport capabilities. Innovative solutions, such as portable and solar-powered biopsy kits, are emerging to overcome these gaps, which achieve high diagnostic accuracy in field deployments.

COMPETITIVE LANDSCAPE

Competition in the biopsy devices market has evolved from rivalry to systemic dominance, where success hinges on interoperability, data fidelity, and clinical workflow integration rather than needle gauge or suction power. Leading firms now compete by designing ecosystems that link imaging modalities, robotic assistance, AI-guided targeting, and genomic compatibility into unified platforms. This shift favors vertically integrated corporations capable of delivering end-to-end diagnostic continuity, which leaves pure-play instrument makers vulnerable. The battlefield is no longer the operating room; it’s the data dashboard. Competitors are increasingly judged by how accurately their devices contribute to treatment decisions, not just by how cleanly they extract tissue. As regulatory bodies demand evidence of diagnostic impact, competition intensifies around outcomes validation, real-world evidence generation, and seamless integration with digital health infrastructures.

KEY MARKET PLAYERS

Some of the notable companies dominating the global biopsy devices market profiled in this report are

• Medtronic
• Leica Biosystems
• Hologic Inc.
• Boston Scientific Corporation
• Becton
• Cook Medical Inc.
• C.R. Bard Inc.
• Mauna Kea Technologies
• Ethicon EndoSurgery Inc.
• Veran Medical Technologies
• Dickinson and Company
• Fujifilm Medical Systems
• MDxHealth
• Argon Medical Devices Inc.
• Intact Medical Corp.

TOP LEADING PLAYERS IN THE MARKET

• Becton, Dickinson and Company (BD) is one of the largest and most dominant players in the biopsy devices market, with a strong product portfolio that includes a wide range of biopsy needles, guns, and kits. The company benefits from its extensive global distribution network and brand reputation, allowing it to serve hospitals and diagnostic centers in both developed and emerging markets. BD has also been investing in automation and user-friendly technologies, such as the BD Trek bone biopsy kit, which recently recorded significant sales growth in the U.S. due to its efficiency and improved safety features. The company’s broad coverage of biopsy types, including bone and soft tissue, ensures its stronghold in the market and positions it as a reliable provider of essential diagnostic tools.

• Hologic, Inc. is especially recognized for its leadership in breast health technologies and has built a solid reputation with its MRI-guided biopsy systems, vacuum-assisted devices, and breast localization solutions. To strengthen its portfolio, Hologic acquired SOMATEX, a specialist in biopsy site markers and localization technologies, which enhanced its offerings in breast cancer diagnosis and management. The company also markets innovative systems such as the ATEC MRI device, designed to improve speed, comfort, and accuracy during breast biopsy procedures. While Hologic has faced regulatory challenges, including FDA warnings on certain marker implants like BioZorb due to complications, the company continues to innovate and invest in breast health, combining imaging, biopsy, and marker technologies to deliver comprehensive solutions for healthcare providers.

• Medtronic plc distinguishes itself in the biopsy devices market through its focus on advanced imaging and navigation-assisted biopsy systems, particularly for complex procedures such as lung cancer diagnosis. Its SuperDimension navigation platform, combined with the GenCut core biopsy tool, allows physicians to extract larger and more intact tissue samples from hard-to-reach lung lesions, improving the accuracy of diagnosis and enabling molecular testing. Medtronic also explores integration of biopsy and treatment by developing tools like the Emprint ablation catheter system, which has received FDA Breakthrough Designation for treating lung lesions. With its strong R&D pipeline and ability to integrate imaging, navigation, and therapy, Medtronic is positioned as a technology-driven innovator addressing the growing need for precision diagnostics in complex cancers.

TOP STRATEGIES USED BY KEY MARKET PARTICIPANTS

Key players are prioritizing ecosystem integration over product innovation alone, embedding biopsy devices within broader diagnostic pipelines that span imaging, genomics, and digital pathology. Strategic partnerships with diagnostic laboratories and AI developers enable seamless sample-to-result workflows by eliminating manual handoffs. Companies are investing heavily in robotics and real-time tissue characterization technologies to reduce operator dependency and improve reproducibility. Regulatory pathways are being accelerated through FDA Breakthrough Device designations tied to novel biomarker-guided sampling.

GLOBAL BIOPSY DEVICES MARKET NEWS

• In January 2021, Hologic Inc. acquired Somatex Medical Technologies GmbH. With this acquisition, Hologic increases its sales presence in Europe by enlarging its channel in Germany. Somatex focuses on developing and manufacturing minimally invasive surgeries in tumor diagnostics and a biopsy to continue its breast health portfolio growth.
• In February 2019, Medtronic retained the Synergy Cranial Software and StealthStation S7. The Synergycranial software and Stealth Station S7 surgical navigation system deliver complete 3-dimensional images of the patient's brain, assisting the neurosurgeons in handling surgical tools and implants used during brain surgery.
• In July 2019, Fujifilm Medical Systems Inc.U.S.A.A ex, tended its breast imaging solutions by introducing its Tomosynthesis Biopsy option for the Aspire Cristalle mammography system. Tomosynthesis is used to determine the 3-D coordinates of the suspicious lesion in the breast.
• In September 2018, Olympus won the FDA clearance for its EZ Shot 3-plus G, a single-use endoscopic ultrasound fine needle for fine needle aspiration and delicate needle biopsy procedures. The Shot 3plus is used to perform methods on submucosal and extramural lesions over the GI tract.

MARKET SEGMENTATION

This research report on the global biopsy devices market has been segmented & sub-segmented based on the product, type, application, end-user, and region.

By Product

• Instruments
  • Manual
  • Automated
  • Semi-automated
• Consumables
  • Reagents
  • Kits

By Type

• Needle Biopsy
  • core needle biopsy
  • fine-needle biopsy
  • vacuum-assisted biopsy
• Surgical Biopsy
  • Incisional biopsy
  • Excisional biopsy

By Application

• Scientific Research
• Medical Diagnosis
• Agricultural Applications
• Genetic Fingerprinting
• Sex Determination

By End User

• Pharmaceutical and Biology Industry
• Academic Research Institute
• Contract Research Organizations
• Forensic Labs

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa